Inactive Instrument

Company OASA PHARADR Nasdaq

Equities

US67421W1099

Pharmaceuticals

Business Summary

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Sales per Business

SEK in Million2021Weight2022Weight Delta
Pharmaceutical Products
100.0 %
26 100.0 % 1 100.0 % -96.12%

Sales per region

SEK in Million2021Weight2022Weight Delta
Other Countries
100.0 %
-- 1 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 66 23-01-22
Director of Finance/CFO 64 20-11-30
Chief Tech/Sci/R&D Officer 55 21-02-28
General Counsel 57 21-09-30

Members of the board

Members of the board TitleAgeSince
Chairman 44 19-03-18
Director/Board Member 59 19-09-25
Director/Board Member 41 22-05-24
Director/Board Member 59 22-05-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 538,043,000 330,469,658 ( 61.42 %) 0 61.42 %

Shareholders

NameEquities%Valuation
OP Asset Management Ltd.
0.2672 %
1,437,868 0.2672 % 41 756 $
Storebrand Asset Management AS
0.0817 %
439,703 0.0817 % 12 769 $
Case Kapitalförvaltning AB
0.0178 %
95,832 0.0178 % 2 783 $
Gustavia Fonder AB
0.0118 %
63,286 0.0118 % 1 838 $
Coeli Asset Management AB
0.005675 %
30,535 0.005675 % 887 $
Evli Fund Management Co. Ltd.
0.005326 %
28,656 0.005326 % 832 $

Company contact information

Vivesto AB

Box 3061

169 03, Solna

+46 18 50 54 40

http://www.oasmia.com
address OASA PHARADR